Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients with Advanced Prostate Cancer
Study identifier:D6874C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Treatment Protocol to Monitor the Safety of a 200 mg Daily Dose of Bicalutamide (Casodex) in Patients with Advanced Prostate Cancer
Medical condition
prostate cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Bicalutamide
Sex
Male
Actual Enrollment
101
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 1994
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Jun 2013
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 200 mg Casodex | Drug: Bicalutamide 200mg daily Other Name: Casodex |
